Intersect ENT, Inc.

Is Magneto the Hero We Need to Destroy Blood Clots? Unlike the Marvel Universe character by the same name, this Magneto is battling blood clots with a device based on electric fields. This Company Is Reinventing the Heart Valve Foldax is trying to eliminate the tradeoff between mechanical and tissue heart valves by starting from scratch. Medtronic Hits an FTC Roadblock in Intersect ENT Deal The Federal Trade Commission wants Medtronic to divest an Intersect ENT subsidiary as a condition of the deal. Bioventus Needs to Find Another Way to Pay for CartiHeal The company has nixed a $415 sale of senior notes that was meant to fund its acquisition of CartiHeal. Can Globus Turn Things Around in a Competitive Spine Market? The company will need to rebound in the second quarter to earn back investor confidence. Could HF be Diagnosed with Just an MRI? Researchers found that MRI could be a reliable and safe option all while avoiding an invasive procedure. Would You Take a Poop Pill? Fecal transplants have been proven effective at treating C. diff, but current delivery methods are lacking. Is stool encapsulation the answer? Medtronic Wins FDA Nod for Onyx Frontier DES The Dublin-based company said the device is the latest innovation in the Resolute DES family. Most Anticipated New Medical Devices in 2022 These medical devices are expected to hit the U.S. market in 2022. Elekta's Esprit Will Enable More Personalized Radio-surgery Elekta’s new radiosurgery system, Esprit, features sub-millimeter accuracy and allows treatment planning in less than 60 seconds. How Nufabrx Is Changing the Medical Landscape What if your medications could be delivered by your clothing?

GOLETA, Calif.--(BUSINESS WIRE)-- Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Tom West to Inogen’s Board of Directors, effective April 1, 2023. The company also announced that Kristen Miranda, who has served as a director since March 2021, will retire as a member of the Board of Directors, effective March 31, 2023. “We are pleased to welcome Tom West to the Inogen Board. Tom brings additional general management and operational experience to the Inogen Board with his history of leadership and business success in medical technology and life sciences healthcare spaces,” said Elizabeth Mora, Chairperson of the Board. “Under the leadership of Nabil Shabshab, Inogen’s President and CEO, we have made significant progress in rebuilding Inogen into a MedTech company that is capable of delivering durable growth as we successfully execute on our strategic initiatives, advance our prescriber growth strategy and drive productivity and efficiency of our commercial operations. The addition of Tom West will further elevate the partnership between the Board and the executive team to advance Inogen’s transformation into a global respiratory care leader.” “On behalf of the Board of Directors, I would also like to thank Kristen Miranda for her commitment and many valuable contributions to the Board,” said Ms. Mora. "She has brought a lot of experience and thought partnership around the healthcare space and channel dynamics, specifically around the aspects of consumer health.” Tom West serves as President and Chief Executive Officer and is an executive Director of the Board of Nalu Medical, Inc., a privately held medical technology company focused on neurostimulation to treat chronic intractable pain. He joined Nalu in August 2022. Before joining Nalu, Mr. West served from 2019 to 2022 as President, Chief Executive Officer and Director at Intersect ENT, Inc., a publicly traded medical device and drug delivery company in the sinus surgery space. Intersect ENT was acquired by Medtronic in May of 2022 doubling its enterprise value in less than three years despite the COVID pandemic. Prior to Intersect, Mr. West served as Worldwide President, Diagnostic Solutions at Hologic from 2015 to 2019. Mr. West began his healthcare career at Johnson & Johnson where he assumed roles of increasing responsibility over a twenty-three-year tenure including Worldwide President of Strategy and Business Development for the J&J Family of Diabetes Solutions Companies, Division President of LifeScan North America and Division President of LifeScan Europe, Middle East and Africa. Mr. West served as an independent member of the Board of Directors of publicly traded Orthofix from 2021 to 2023. He has also been a member of the Board of medical technology trade associations, AdvaMed and Biocom California. Mr. West received a B.A. in Politics and Economics from Princeton University and an MBA from the University of Pennsylvania, Wharton School. “I am thrilled to have the opportunity to advance Inogen’s transformation into a global respiratory care leader,” said Tom West. “Inogen has been an industry innovator, I look forward to adding my operating experience accelerating growth opportunities to help the Company enhance the value it delivers to its patients, customers and shareholders.” In connection with the appointment, Mr. West will be joining the Compliance Committee as well as the Nominating and Governance Committee of the Board. About Inogen Inogen, Inc. (Nasdaq: INGN) is a leading global medical technology company offering innovative respiratory products for use in the homecare setting. Inogen supports patient respiratory care by developing, manufacturing, and marketing innovative best-in-class portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Inogen partners with patients, prescribers, home medical equipment providers, and distributors to make its oxygen therapy products widely available allowing patients the chance to remain ambulatory while managing the impact of their disease. For more information, please visit . Inogen has used, and intends to continue to use, its Investor Relations website, , as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit . Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements with respect to the announced changes to Inogen’s board of directors; statements concerning or implying Inogen’s future financial performance; statements regarding Inogen’s goals and potential, including the potential for Inogen to achieve durable growth; statements regarding the partnership between Inogen’s board of directors and management; the ability of management and board of directors personnel to contribute to the execution of Inogen’s strategic plans and goals; and the ability of Inogen to become a prominent leader in respiratory care. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,” “intends,” “potential,” “possible,” and similar expressions are intended to identify forward-looking statements. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks related to its announced management and organizational changes, and risks arising from the possibility that Inogen will not realize anticipated future financial performance or strategic goals. In addition, Inogen's business is subject to numerous additional risks and uncertainties, including, among others, risks relating to market acceptance of its products; competition; its sales, marketing and distribution capabilities; its planned sales, marketing, and research and development activities; interruptions or delays in the supply of components or materials for, or manufacturing of, its products; seasonal variations; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting Inogen’s business operating results are contained in its Annual Report on Form 10-K for the period ended December 31, 2021, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Inogen disclaims any obligation to update these forward-looking statements except as may be required by law.

Intelligent upstream bioprocess development for therapeutics using an integrated platform of cloud-based software, single-use bioreactors, simulation tools, and process development services. New leadership team members enhance company expertise in the biotech and biopharma industriesSan Francisco, March 14, 2023 (GLOBE NEWSWIRE) -- SAN FRANCISCO, March 14, 2023 (GLOBE NEWSWIRE) – Culture Biosciences today announced that it is increasing its focus on upstream bioprocess development of new therapeutics. New leaders for Operations and Commercial, Engineering and Product, Strategy and Finance, and People enhance Culture Biosciences’ expertise in the biotech and biopharma industries. “The potential of new biologic therapies, including cell and gene therapies, to improve the lives of people with severe diseases, has exploded over the past years,” said Will Patrick, Chief Executive Officer of Culture Biosciences. “However, developing scalable and optimized manufacturing processes remains a bottleneck for the industry. Lack of innovation in upstream bioprocess development plays an important role. Going forward, we will focus our know-how, technology and services to tackle this problem to help accelerate the development of scalable, optimized manufacturing processes for the benefit of patients.” The appointments of Elena Cant as Chief Operating and Commercial Officer, Babu Sivaraman as Vice President, Engineering and Product, Sumeet Agrawal as Vice President, Strategy and Finance, and Wayne Evans as Vice President, People between Q3 2022 and March 2023 underpin this enhanced focus. “The combined experience of Elena, Babu, Sumeet, and Wayne will help us succeed in this next chapter,” added Will Patrick. “I am delighted to welcome such strong leaders to our great team, and I look forward to working with them to create better tools and services for upstream bioprocess development for biotech and biopharma companies.” “I have experienced the need for faster and more cost-efficient upstream bioprocess development in biopharma R&D first-hand. The de-risking of manufacturing timelines by completing process optimization and characterization in advance of GMP manufacturing is just one example,” said Elena Cant, Chief Operating and Commercial Officer. “Together with my colleagues, I am looking forward to expanding Culture Biosciences’ offerings to help more companies in this sector succeed.” Client companies can use Culture Biosciences’ platform instead of investing the time and capital to build-out in-house process development capacity. Or they can leverage it to flexibly handle fluctuations in process development needs as a result of evolving strategies or pipelines. About the new leadership team membersElena Cant has more than 20 years of experience in corporate development, business operations, strategy, marketing, commercial, manufacturing, and R&D in large and small global biopharmaceutical companies. She joined Culture Biosciences from TwinStrand Biosciences where she served as Chief Operating Officer. Prior to TwinStrand, Elena held senior roles at Takeda Pharmaceuticals, Hospira and Mead Johnson Nutrition, McKinsey & Company (working with major pharmaceutical and medical device companies), and IBM Business Consulting Services/PWC Consulting. She serves as a Director on the Board of Directors of Societal CDMO, Inc. Elena has an MBA from the University of Chicago and a Bachelor of Science degree from the Technical University of Moldova. Babu Sivaraman, PhD, has more than 16 years of experience in the development and commercialization of modern and differentiated bioprocessing solutions in the life sciences industry. Prior to joining Culture Biosciences, he held leading roles at Thermo Fisher Scientific’s Bioproduction group and Fluor’s Life Sciences and Advanced Manufacturing group. Babu has a PhD in Engineering and a Master of Science degree from the University of Florida, and a Bachelor of Engineering degree from the University of Madras, India. He is a licensed Professional Engineer in the State of California. Sumeet Agrawal has more than 15 years of experience in capital raising, M&A, and financial leadership in support of drug development, manufacturing and launch in the global pharmaceutical, cell therapy, medical device, and synthetic biology industries. Prior to joining Culture Biosciences, he held leading Finance roles at Instil Bio, Intersect ENT, and Genentech. Sumeet has an MBA from Indiana University, a Master of Science degree from the University of Toledo and a Bachelor degree from the University of Mumbai, India. Wayne Evans, SPHR-SCP, has more than 30 years of HR leadership experience in the sectors of IT, network security, data storage, and laser-based MEMS sensing and display, and more recently in life sciences companies driving innovation in clinical trials management and genomic technologies. He joins Culture Biosciences from TwinStrand Biosciences where he served as Head of HR. Prior to TwinStrand, Wayne held leading roles in private and public companies at different development stages with different business strategies, including M&A, and regional, national, and international expansion. He has an MBA from Seattle University, and a Bachelor of Arts degree from Whitman College, in Walla Walla, WA. About Culture Biosciences’ propriety upstream bioprocess development platformCustomers design and monitor their experiments, collaborate on projects, and access and analyze data on a fully integrated platform that combines: 250mL bioreactors and 5L bioreactors, each with single-use vessels for mammalian cell lines or microbial fermentation. The 250mL reactors are mounted in mobile cart modules of four units. Dedicated and proprietary, cloud-based software to design and monitor experiments remotely, and to integrate and analyze data in one place. Remote, hybrid or multi-location teams can collaborate virtually on this platform. A suite of proprietary tools for process design and data analysis. These tools include a dynamic data analysis suite that enables rapid analysis and understanding of process and offline analytical data. More than 70 client companies have trusted Culture Biosciences’ platform with their upstream bioprocess development in the 5 years since beginning operations in 2018. Customers include large, top-10 biopharma companies, leading CDMOs, and emerging and growing biotech clients. About Culture BiosciencesCulture Biosciences is dedicated to innovation in upstream bioprocess development. Culture’s goal is to build new tools and services that improve the performance, time-to-develop, and cost-efficiency of therapeutic manufacturing processes. The company’s proprietary, fully integrated platform combines bioreactors, cloud-based software, and services to offer client companies around the world access to predictable, and scalable bioprocess development. Culture Biosciences was founded in 2016 and is based in South San Francisco, CA. www.culturebiosciences.com